Next Article in Journal
A Coralline Algal-Associated Bacterium, Pseudoalteromonas Strain J010, Yields Five New Korormicins and a Bromopyrrole
Next Article in Special Issue
In Situ Detection of Antibiotic Amphotericin B Produced in Streptomyces nodosus Using Raman Microspectroscopy
Previous Article in Journal / Special Issue
Actinomycetes from Red Sea Sponges: Sources for Chemical and Phylogenetic Diversity
Article Menu

Export Article

Open AccessArticle
Mar. Drugs 2014, 12(5), 2790-2801;

Marine Compound Catunaregin Inhibits Angiogenesis through the Modulation of Phosphorylation of Akt and eNOS in vivo and in vitro

Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
Department of Clinical Laboratory, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China
Guangdong Key Laboratory for Diagnosis and Treatment of Major Neurological Diseases, Department of Neurology, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China
Jiaxing University College of Medicine, Jiaxing 314001, China
CAS Key Laboratory of Tropical Marine Bio-resources and Ecology, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China
These two authors contributed equally to the work.
Authors to whom correspondence should be addressed.
Received: 10 February 2014 / Revised: 9 April 2014 / Accepted: 14 April 2014 / Published: 12 May 2014
(This article belongs to the Special Issue Advances and New Perspectives in Marine Biotechnology)
Full-Text   |   PDF [991 KB, uploaded 24 February 2015]   |  


Angiogenesis is the formation of blood vessels from pre-existing vasculature. Excessive or uncontrolled angiogenesis is a major contributor to many pathological conditions whereas inhibition of aberrant angiogenesis is beneficial to patients with pathological angiogenesis. Catunaregin is a core of novel marine compound isolated from mangrove associate. The potential anti-angiogenesis of catunaregin was investigated in human umbilical vein endothelial cells (HUVECs) and zebrafish. HUVECs were treated with different concentrations of catunaregin in the presence or absence of VEGF. The angiogenic phenotypes including cell invasion cell migration and tube formation were evaluated following catunaregin treatment in HUVECs. The possible involvement of AKT, eNOS and ERK1/2 in catunaregin-induced anti-angiogenesis was explored using Western blotting. The anti-angiogenesis of catunaregin was further tested in the zebrafish embryo neovascularization and caudal fin regeneration assays. We found that catunaregin dose-dependently inhibited angiogenesis in both HUVECs and zebrafish embryo neovascularization and zebrafish caudal fin regeneration assays. In addition, catunaregin significantly decreased the phosphorylation of Akt and eNOS, but not the phosphorylation of ERK1/2. The present work demonstrates that catunaregin exerts the anti-angiogenic activity at least in part through the regulation of the Akt and eNOS signaling pathways. View Full-Text
Keywords: anti-angiogenesis; catunaregin; VEGF; zebrafish; HUVECs anti-angiogenesis; catunaregin; VEGF; zebrafish; HUVECs

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Liu, J.-X.; Luo, M.-Q.; Xia, M.; Wu, Q.; Long, S.-M.; Hu, Y.; Gao, G.-C.; Yao, X.-L.; He, M.; Su, H.; Luo, X.-M.; Yao, S.-Z. Marine Compound Catunaregin Inhibits Angiogenesis through the Modulation of Phosphorylation of Akt and eNOS in vivo and in vitro. Mar. Drugs 2014, 12, 2790-2801.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top